186 related articles for article (PubMed ID: 32489798)
1. Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study.
Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Kamstrup PR; Faber J; Køber L; Schou M
Glob Heart; 2020 Mar; 15(1):25. PubMed ID: 32489798
[TBL] [Abstract][Full Text] [Related]
2. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Hansen PM; Kamstrup PR; Faber J; Køber L; Schou M
Biomarkers; 2020 May; 25(3):248-259. PubMed ID: 32126847
[No Abstract] [Full Text] [Related]
4. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
[TBL] [Abstract][Full Text] [Related]
5. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
Hauser JA; Demyanets S; Rusai K; Goritschan C; Weber M; Panesar D; Rindler L; Taylor AM; Marculescu R; Burch M; Wojta J; Michel-Behnke I
Heart; 2016 Oct; 102(20):1633-9. PubMed ID: 27220692
[TBL] [Abstract][Full Text] [Related]
7. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
8. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
Charitakis E; Walfridsson H; Alehagen U
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
[TBL] [Abstract][Full Text] [Related]
9. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
12. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
13. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
[TBL] [Abstract][Full Text] [Related]
15. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
[TBL] [Abstract][Full Text] [Related]
16. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
[TBL] [Abstract][Full Text] [Related]
17. Relationship between body mass index, cardiovascular biomarkers and incident heart failure.
Suthahar N; Meems LMG; Groothof D; Bakker SJL; Gansevoort RT; van Veldhuisen DJ; de Boer RA
Eur J Heart Fail; 2021 Mar; 23(3):396-402. PubMed ID: 33443299
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
[TBL] [Abstract][Full Text] [Related]
20. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
